Bupivacaine/meloxicam

Bupivacaine/meloxicam
Combination of
Bupivacaine	Local anesthetic
Meloxicam	Nonsteroidal anti-inflammatory drug (NSAID)
Clinical data
Trade names	Zynrelef
Other names	HTX-011
License data	EU EMA: by INN; US DailyMed: Bupivacaine_and_meloxicam;
Routes of; administration	Intralesional, infiltration
ATC code	N01BB59 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	2561486-80-2;
KEGG	D12270;

Bupivacaine/meloxicam, sold under the brand name Zynrelef, is a fixed-dose combination medication used to treat pain in small to medium-sized wounds after surgery.^[1]^[2]^[4] It contains bupivacaine and meloxicam.^[1]^[2]

The most common side effects of bupivacaine/meloxicam are dizziness, constipation, vomiting, and headache.^[1]^[2]

It was approved for medical use in the European Union in September 2020,^[2] and in the United States in May 2021.^[1]^[5]

Medical uses

In the European Union, the combination bupivacaine/meloxicam is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.^[2]

In the United States it is indicated for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty in adults.^[1]^[5]

References

^ ^a ^b ^c ^d ^e ^f "Zynrelef- bupivacaine and meloxicam solution". DailyMed. Retrieved 8 January 2022.
^ ^a ^b ^c ^d ^e ^f "Zynrelef EPAR". European Medicines Agency (EMA). 22 July 2020. Retrieved 6 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Zynrelef Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^ Blair HA (July 2021). "Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain". Drugs. 81 (10): 1203–1211. doi:10.1007/s40265-021-01551-9. PMID 34228280. S2CID 235744803.
^ ^a ^b "Heron Therapeutics Announces U.S. FDA Approval of Zynrelef (HTX-011) for the Management of Postoperative Pain for up to 72 Hours" (Press release). Heron Therapeutics. 13 May 2021. Retrieved 14 May 2021 – via PR Newswire.

External links

"Bupivacaine mixture with meloxicam". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT03295721 for "Bunionectomy Study for Postoperative Analgesia (EPOCH 1)" at ClinicalTrials.gov
Clinical trial number NCT03237481 for "Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)" at ClinicalTrials.gov
Clinical trial number NCT03015532 for "Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia" at ClinicalTrials.gov

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[Zynrelef_FDA_label-1] ^ ^a ^b ^c ^d ^e ^f "Zynrelef- bupivacaine and meloxicam solution". DailyMed. Retrieved 8 January 2022.

[Zynrelef_EPAR-2] ^ ^a ^b ^c ^d ^e ^f "Zynrelef EPAR". European Medicines Agency (EMA). 22 July 2020. Retrieved 6 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[3] "Zynrelef Product information". Union Register of medicinal products. Retrieved 3 March 2023.

[Blair_2021-4] Blair HA (July 2021). "Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain". Drugs. 81 (10): 1203–1211. doi:10.1007/s40265-021-01551-9. PMID 34228280. S2CID 235744803.

[Heron_Therapeutics_PR-5] "Heron Therapeutics Announces U.S. FDA Approval of Zynrelef (HTX-011) for the Management of Postoperative Pain for up to 72 Hours" (Press release). Heron Therapeutics. 13 May 2021. Retrieved 14 May 2021 – via PR Newswire.

[1]

[2]

[3]

[4]

[5]

v t e Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
pyrazolones / pyrazolidines	Aminophenazone Ampyrone Azapropazone Clofezone Difenamizole Famprofazone Feprazone Kebuzone Metamizole Mofebutazone Morazone Nifenazone Oxyphenbutazone Phenazone Phenylbutazone Propyphenazone Sulfinpyrazone Suxibuzone^‡
salicylates	Aspirin (acetylsalicylic acid)^# Aloxiprin Benorylate Carbasalate calcium Diflunisal Dipyrocetyl Ethenzamide Guacetisal Magnesium salicylate Methyl salicylate Salsalate Salicin Salicylamide Salicylic acid (salicylate) Sodium salicylate
acetic acid derivatives and related substances	Aceclofenac Acemetacin Alclofenac Amfenac Bendazac Bromfenac Bufexamac Bumadizone Diclofenac Difenpiramide Etodolac Felbinac Fenclozic acid Fentiazac Indometacin Indometacin farnesil Isoxepac Ketorolac Lonazolac Mofezolac Oxametacin Prodolic acid Proglumetacin Sulindac Tiopinac Tolmetin Zomepirac^†
oxicams	Ampiroxicam Droxicam Isoxicam Lornoxicam Meloxicam Piroxicam Pivoxicam Tenoxicam
propionic acid derivatives (profens)	Alminoprofen Benoxaprofen^† Carprofen^‡ Dexibuprofen Dexketoprofen Fenbufen Fenoprofen Flunoxaprofen Flurbiprofen Ibuprofen^# Ibuproxam Indoprofen^† Ketoprofen Loxoprofen Miroprofen Naproxen Oxaprozin Pelubiprofen Piketoprofen Pirprofen Suprofen Tarenflurbil Tepoxalin^‡ Tiaprofenic acid Vedaprofen^‡ Zaltoprofen COX-inhibiting nitric oxide donator: Naproxcinod
n-arylanthranilic acids (fenamates)	Azapropazone Clonixin Etofenamate Floctafenine Flufenamic acid Flunixin Flutiazin Glafenine^† Meclofenamic acid Mefenamic acid Morniflumate Niflumic acid Tolfenamic acid
COX-2 inhibitors (coxibs)	Apricoxib Celecoxib (+tramadol) Cimicoxib^‡ Deracoxib^‡ Etoricoxib Firocoxib^‡ Lumiracoxib^† Mavacoxib^‡ Parecoxib Robenacoxib^‡ Rofecoxib^† Valdecoxib^†
other	Aminopropionitrile Benzydamine Chondroitin sulfate Diacerein Fluproquazone Glucosamine Glycosaminoglycan Hyperforin Nabumetone Nimesulide Oxaceprol Proquazone Superoxide dismutase / orgotein Tenidap
NSAID combinations	Ibuprofen/famotidine Ibuprofen/hydrocodone Ibuprofen/oxycodone Ibuprofen/paracetamol Meloxicam/bupivacaine Naproxen/diphenhydramine Naproxen/esomeprazole
Key: underline indicates initially developed first-in-class compound of specific group; ^#WHO-Essential Medicines; ^†withdrawn drugs; ^‡veterinary use.
category commons portal